Global Clinical Trial Imaging in Oncology with AI and Radiomics Market Size, Trends & Growth Opportunity By Imaging Service Type, By Trial Phase, By Oncology Indication, By Customer Type, By Region and Forecast Till 2030

Report ID : AMR1005988 | Industries : Healthcare | Published On :August 2026 | Page Count : 237

Request Sample
Ask for Customization

The global clinical trial imaging in oncology market covers imaging CRO services, biomarker quantification and trial endpoint optimization using AI and radiomics for oncology drug development.

Clinical trial imaging is the use of medical imaging, combined with AI-based analysis and radiomics, to generate and validate endpoints in oncology clinical trials, and this report describes the category strictly as a market segment.

It makes no claim about regulatory credibility effectiveness, imaging standardization effectiveness, or AI validation effectiveness for any product or company described on these pages.

Seven segmentation dimensions appear in this report, and the first two describe the imaging service type supplied and the AI/radiomics capability layer it uses.

Imaging service type spans four categories, from core lab imaging services and imaging data management/workflow platforms through endpoint analysis and statistical validation, and imaging trial design consulting.

AI and radiomics capability layer covers four categories, spanning feature extraction and radiomics pipelines, AI-based tumor segmentation and volumetrics, predictive modeling, and multi-modal data fusion.

The most useful commercial observation about this market is that trial endpoint requirements, not imaging service type label alone, is the specification decision made first.

What endpoint a trial must validate determines which AI/radiomics capability layers are even viable before a sponsor settles on a preferred imaging service type.

Business model/engagement type spans four categories including full-service imaging CRO model, hybrid CRO and AI analytics partnership, SaaS-based imaging analytics platforms, and strategic partnerships with pharma sponsors, and imaging modality is a further dimension covering CT, MRI, PET/CT and PET/MRI, ultrasound, and hybrid/multi-modality imaging.

Trial phase covers four categories including Phase I, Phase II, Phase III, and post-marketing/real-world evidence studies, and oncology indication spans six categories including lung, breast, prostate and colorectal cancer, CNS tumors, and hematologic malignancies.

Customer type completes a further dimension across pharmaceutical companies, biotechnology firms, contract research organizations, academic research institutions, and government/cooperative oncology groups.

This report covers clinical trial imaging and AI/radiomics services delivered globally across the regions and countries listed above.

It excludes diagnostic imaging equipment manufacturing and non-oncology clinical trial imaging outside this report's scope.

Buyer intelligence in the full report maps this landscape across large pharma, mid-size biotech and niche oncology innovators, spanning oncology drug development, precision medicine and immunotherapy.

Market Size & Growth Forecast (2026 to 2030)

The global clinical trial imaging in oncology market is estimated at approximately USD 950 Million in 2025 and is projected to reach approximately USD 2.05 Billion by 2030, expanding at a compound annual growth rate of roughly 16.6 percent.

The estimate covers clinical trial imaging, AI and radiomics analytics services for oncology drug development, and excludes diagnostic imaging equipment manufacturing and non-oncology clinical trial imaging.

Core lab imaging services account for the largest imaging service type category by revenue, while AI-based tumor segmentation and volumetrics form the fastest-growing AI/radiomics capability layer.

CT and MRI together account for the largest imaging modality category, and PET/CT and PET/MRI form a fast-growing modality category tied to expanding metabolic imaging use.

Phase III trials account for the largest trial phase category by revenue, and Phase I trials form a fast-growing category tied to rising early imaging biomarker adoption.

Lung cancer and breast cancer together account for the largest oncology indication category, and CNS tumors form a fast-growing indication tied to expanding neuro-oncology trial activity.

Full-service imaging CRO models together with hybrid CRO and AI analytics partnerships account for the largest business model category, and SaaS-based imaging analytics platforms form the fastest-growing category.

Pharmaceutical companies together with contract research organizations account for the largest customer type category identified in this report.

North America accounts for the largest regional concentration in this report, and Asia-Pacific forms a fast-growing region tied to expanding oncology trial activity.

The forecast assumes global oncology drug development investment continues broadly on recent trends, and a sustained slowdown in oncology R&D funding would move the trajectory.

MetricValue
Market Size (2025)Approximately USD 950 Million
Forecast Size (2030)Approximately USD 2.05 Billion
CAGR (2025-2030)Approximately 16.6%
Base Year2025
Forecast Period2026-2030 (5-year)
Scope NoteClinical trial imaging, AI and radiomics analytics for oncology only; excludes diagnostic imaging equipment and non-oncology imaging
Largest Imaging Service TypeCore lab imaging services
Fastest-Growing AI/Radiomics LayerAI-based tumor segmentation and volumetrics
Largest Trial Phase CategoryPhase III (endpoint-driven large-scale trials)
Largest Oncology IndicationLung cancer, breast cancer
Fastest-Growing Oncology IndicationCNS tumors
Largest Regional ConcentrationNorth America

Market Drivers

Growth in oncology drug development pipelines, sustaining demand for imaging biomarker quantification and trial endpoint validation.

Rising adoption of AI-based tumor segmentation and predictive modeling, driving demand for radiomics-enabled imaging CRO services.

Expansion of precision medicine and immunotherapy trial activity, requiring multi-modal data fusion combining imaging, genomics and clinical data.

Increasing regulatory acceptance of imaging biomarkers, broadening demand for AI validation and regulatory-credible imaging analytics.

Growth in decentralized and hybrid trial models, sustaining demand for cloud-based imaging platforms and remote data management.

Rising investment in AI platform acquisitions by CROs, broadening the field of full-service providers offering integrated AI capability.

Expansion of CNS and hematologic malignancy trial activity, requiring specialised imaging expertise beyond common solid tumor indications.

Growth in SaaS-based imaging analytics adoption, offering sponsors a scalable alternative to traditional full-service engagement models.

Together these drivers point toward a market where AI-enabled, quantitative imaging demand grows faster than traditional core lab imaging alone, even though core lab volume remains the largest single service category.

TECHNOLOGY WATCH

AI-based tumor segmentation and volumetrics is expanding faster than any other AI/radiomics capability layer tracked in this market, and rising investment in AI platform acquisitions by CROs is broadening the field of full-service providers able to offer that capability directly rather than through a separate specialist partner.

 

Market Restraints

Dependence on pharma and biotech clinical trial budgets, which govern new demand and are outside any provider's control.

Long procurement cycles, typically 3 to 9 months, before an imaging services engagement reaches trial execution.

Competition between global imaging CRO specialists and AI-first imaging analytics firms, which fragments technical and commercial preference.

Regulatory delays, data variability and AI explainability concerns, which bear directly on adoption pace and trial timelines.

Fragmented demand across smaller, niche oncology innovators, which raises the cost of serving that segment commercially relative to top-tier pharma engagements.

Extended sales cycle periods for multi-phase, bundled CRO contracts, which can lengthen a provider's time to execution.

Long qualification periods before a pharma sponsor approves a new imaging or AI analytics vendor relationship.

Skilled radiomics and imaging science personnel availability constraints, which can affect both new platform development and ongoing customer technical support capacity.

Market Opportunities

Limited AI validation in smaller CROs identified in the report competitive mapping.

Underpenetration in APAC oncology trials identified in the report competitive mapping.

Gap in integrated imaging and multi-omics analytics, leaving room for combined data fusion offerings.

Opportunity for scalable SaaS imaging analytics, where fewer providers have established deep platform-based delivery capability.

Underserved demand in CNS and hematologic malignancy imaging, where fewer providers have established deep specialised expertise.

Expansion of deep learning radiomics technology, which several providers are using to differentiate their AI offering.

Growth in hybrid CRO and AI analytics partnership participation, offering a growing alternative business model to full-service engagement alone.

Multi-modality imaging capability, which reduces the number of separate provider relationships a sponsor must maintain across varied trial requirements.

Together these opportunities point toward the widest remaining commercial gap sitting between traditional core lab imaging and fully integrated, multi-omics-enabled analytics platforms.

Imaging Service Types and AI/Radiomics Capability Layers

Buyers evaluating how core lab imaging services, imaging data management and workflow platforms, endpoint analysis and statistical validation, and imaging trial design consulting integrate with feature extraction, AI-based tumor segmentation, predictive modeling and multi-modal data fusion increasingly narrow their shortlist around imaging service types and AI capability layers that match a trial's endpoint requirements.

Imaging Business Models and Modalities

Full-service imaging CRO models, hybrid CRO and AI analytics partnerships, SaaS-based imaging analytics platforms, and strategic partnerships with pharma sponsors span CT, MRI, PET/CT, PET/MRI, ultrasound and hybrid multi-modality imaging, and the resulting imaging business models and modalities pairing shapes which providers a sponsor can realistically shortlist.

Imaging Trial Phases and Oncology Indications

Phase I, Phase II, Phase III and post-marketing/real-world evidence studies span lung, breast, prostate and colorectal cancer, CNS tumors and hematologic malignancies, and this spread of imaging trial phases and oncology indications shapes how quickly a sponsor can identify the right imaging partner.

Imaging Customer Types

Pharmaceutical companies, biotechnology firms, contract research organizations, academic research institutions, and government/cooperative oncology groups engage clinical trial imaging providers across this report's business model categories, a mix of imaging customer types that varies considerably by trial phase and oncology indication.

Clinical Trial Imaging in Oncology Market, By Region

This report covers North America, Europe and Asia-Pacific, reflecting where global oncology drug development activity is concentrated.

North America accounts for the largest regional concentration in this report, covered through the United States (Arizona, California, Massachusetts and North Carolina), reflecting concentrated biotech and clinical trial hub activity.

Europe, covered through the United Kingdom, Germany, France, Switzerland and the Netherlands, represents a substantial regional concentration tied to established oncology research networks.

Asia-Pacific, covering Japan, China, South Korea, Australia and India, forms a fast-growing region tied to expanding oncology trial activity and APAC clinical trial ecosystem investment.

Regional sizing, growth rates and country-level breakdowns are reserved for the full report rather than presented on this page.

REGIONAL OPPORTUNITY

Asia-Pacific's expanding oncology trial activity is outpacing North America's larger, more established base, and the region's clinical trial ecosystem investment across Japan, China, South Korea, Australia and India positions it as the market's clearest growth frontier over the forecast period.

 

Leading Companies

Imaging Endpoints, ICON plc, Parexel, IQVIA, Medpace, BioClinica, Arterys, Lunit, Aidoc, Tempus, Flywheel, Qure.ai and Subtle Medical are covered in the full report. An introduction to the provider landscape by company type is available on the clinical trial imaging AI and radiomics providers page.

Beyond This Page

The full report extends well past the segmentation summarised here and into the commercial detail that shapes how clinical trial imaging engagements are actually won.

Buyer intelligence maps the buyer ecosystem across large pharma, mid-size biotech and niche oncology innovators in full.

Decision-maker mapping covers vendor selection criteria, contract value bands, purchasing decision makers and sales cycle length.

Competitive benchmarking compares providers across estimated market position, pricing tiers, geographic reach and clinical trial experience.

The market playbook covers pricing structure, regulatory shifts, customer behaviour and technology disruption.

Pricing and procurement chapters cover pricing analysis, AI analytics and traditional imaging pricing, buyer and supplier bargaining dynamics and total cost of ownership.

Go-to-market chapters set out entry via CRO and pharma partnerships, AI-enabled differentiation and major oncology industry event participation.

Company profiles cover thirteen companies across footprint, portfolio, certifications and innovation capabilities.

Buyer decision detail extends into how clinical trial budgets and R&D innovation funds are actually approved within a sponsor organisation, not just who signs off on the final order.

Frequently Asked Questions

The market is estimated at approximately USD 950 Million in 2025 and is projected to reach approximately USD 2.05 Billion by 2030, expanding at a compound annual growth rate of roughly 16.6 percent.

The use of medical imaging, combined with AI-based analysis and radiomics, to generate and validate endpoints in oncology clinical trials. This report describes the category strictly as a market segment.

Growth in oncology drug development pipelines is the leading driver, sustaining demand for imaging biomarker quantification and trial endpoint validation.

North America accounts for the largest regional concentration, reflecting concentrated biotech and clinical trial hub activity across the United States.

Core lab imaging services account for the largest imaging service type category by revenue, and are generally specified across the widest range of trial phases and oncology indications.

AI-based tumor segmentation and volumetrics forms the fastest-growing AI/radiomics capability layer, reflecting rising demand for automated, quantitative tumor assessment.

Dependence on pharma and biotech clinical trial budgets outside any provider's control, long procurement cycles typically running 3 to 9 months, and regulatory delays, data variability and AI explainability concerns all bear directly on adoption pace.

Underpenetration in APAC oncology trials and a gap in integrated imaging and multi-omics analytics represent the widest remaining commercial gaps identified in this report's competitive mapping.

Inquire Before Buying Request Free Sample Ask For Discount

1. Introduction

1.1. Objective of the Study

1.2. Market Definition

1.3. Market Scope

2. Executive Summary

3. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis Market Analysis and Forecast (2026–2030)

3.1. Overview

3.2. Market Dynamics

3.3. Drivers

3.3.1. Growth in Oncology Drug Development Pipelines, Sustaining Demand for Imaging Biomarker Quantification and Trial Endpoint Validation.

3.3.2. Rising Adoption of AI-Based Tumor Segmentation and Predictive Modeling, Driving Demand for Radiomics-Enabled Imaging CRO Services.

3.3.3. Expansion of Precision Medicine and Immunotherapy Trial Activity, Requiring Multi-Modal Data Fusion Combining Imaging, Genomics and Clinical Data.

3.3.4. Increasing Regulatory Acceptance of Imaging Biomarkers, Broadening Demand for AI Validation and Regulatory-Credible Imaging Analytics.

3.4. Restraints

3.4.1. Dependence on Pharma and Biotech Clinical Trial Budgets, Which Govern New Demand and Are Outside Any Provider's Control.

3.4.2. Long Procurement Cycles, Typically 3 to 9 Months, Before an Imaging Services Engagement Reaches Trial Execution.

3.4.3. Competition Between Global Imaging CRO Specialists and AI-First Imaging Analytics Firms, Which Fragments Technical and Commercial Preference.

3.4.4. Regulatory Delays, Data Variability and AI Explainability Concerns, Which Bear Directly on Adoption Pace and Trial Timelines.

3.5. Opportunities

3.5.1. Limited AI Validation in Smaller CROs Identified in the Report Competitive Mapping.

3.5.2. Underpenetration in APAC Oncology Trials Identified in the Report Competitive Mapping.

3.5.3. Gap in Integrated Imaging and Multi-Omics Analytics, Leaving Room for Combined Data Fusion Offerings.

3.5.4. Opportunity for Scalable SaaS Imaging Analytics, Where Fewer Providers Have Established Deep Platform-Based Delivery Capability.

3.6. Porter's Five Forces Model

3.7. Value Chain Analysis

4. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Imaging Service Type

4.1. Core Lab Imaging Services (Centralized Reads, Adjudication)

4.2. Imaging Data Management and Workflow Platforms

4.3. Endpoint Analysis and Statistical Validation

4.4. Imaging Trial Design Consulting

5. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, AI and Radiomics Capability Layer

5.1. Feature Extraction and Radiomics Pipelines

5.2. AI-Based Tumor Segmentation and Volumetrics

5.3. Predictive Modeling (Treatment Response, Survival Outcomes)

5.4. Multi-Modal Data Fusion (Imaging, Genomics and Clinical Data)

6. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Imaging Modality

6.1. CT (Computed Tomography)

6.2. MRI (Magnetic Resonance Imaging)

6.3. PET/CT and PET/MRI

6.4. Ultrasound (Limited Oncology Applications)

6.5. Hybrid/Multi-Modality Imaging

7. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Oncology Indication

7.1. Lung Cancer

7.2. Breast Cancer

7.3. Prostate Cancer

7.4. Colorectal Cancer

7.5. CNS Tumors (Glioblastoma, Brain Metastases)

7.6. Hematologic Malignancies (Imaging-Supported Trials)

8. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Trial Phase

8.1. Phase I (Dose Escalation and Early Imaging Biomarkers)

8.2. Phase II (Efficacy and Response Validation)

8.3. Phase III (Endpoint-Driven Large-Scale Trials)

8.4. Post-Marketing/Real-World Evidence Studies

9. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Customer Type

9.1. Pharmaceutical Companies

9.2. Biotechnology Firms

9.3. Contract Research Organizations (CROs)

9.4. Academic Research Institutions

9.5. Government/Cooperative Oncology Groups

10. Clinical Trial Imaging in Oncology with AI and Radiomics Market - Global View with Focus on Imaging CRO Services, Biomarker Quantification and Trial Endpoint Optimization, with Spotlight on Imaging Service Type, AI and Radiomics Capability Layer, Imaging Modality, Oncology Indication, Trial Phase, Customer Type, Business Model, Buyer Intelligence, Competitive Benchmarking and Growth Opportunity Analysis, Business Model / Engagement Type

10.1. Full-Service Imaging CRO Model

10.2. Hybrid CRO and AI Analytics Partnership

10.3. SaaS-Based Imaging Analytics Platforms

10.4. Strategic Partnerships with Pharma Sponsors

11. Clinical Trial Imaging Buyer Intelligence

11.1. Buyer Segmentation

11.1.1. Large Pharma

11.1.2. Mid-Size Biotech

11.1.3. Niche Oncology Innovators

11.2. Buyer Industries

11.2.1. Oncology Drug Development

11.2.2. Precision Medicine

11.2.3. Immunotherapy

11.3. Buyer Company Types

11.3.1. Sponsor-Led Trials

11.3.2. CRO-Outsourced Models

11.4. Geographic Demand Mapping

11.4.1. Country-Wise Buyer Concentration (US, Germany, UK, Japan Dominance)

11.4.2. Regional Demand Clusters (US Biotech Hubs, EU Oncology Research Networks, APAC Expansion Markets)

11.5. Buyer Scale Classification

11.5.1. Top 20 Pharma

11.5.2. Emerging Biotech Pipelines

11.6. Procurement Behaviour

11.6.1. Bundled CRO Contracts

11.6.2. Specialized Imaging Outsourcing

11.7. Buying Triggers

11.7.1. Regulatory Endpoint Requirements

11.7.2. Trial Complexity

11.7.3. Need for Quantification

11.8. Decision Makers

11.8.1. Clinical Operations Heads

11.8.2. Imaging Leads

11.8.3. Biomarker Strategy Teams

11.9. Budget Ownership

11.9.1. Clinical Trial Budgets

11.9.2. R&D (Research and Development) Innovation Funds

11.10. Vendor Selection Criteria

11.10.1. Regulatory Credibility

11.10.2. Imaging Standardization

11.10.3. AI Validation

11.11. Commercial Patterns

11.11.1. Contract Value Bands (Mid-to-High Value Multi-Phase Engagements)

11.11.2. Sales Cycle Length (3 to 9 Months Depending on Trial Phase)

11.11.3. Strategic Relevance for Endpoint Validation, Trial Acceleration and Regulatory Success

12. Global Market Analysis and Forecast (2026–2030)

12.1. Introduction

12.2. Market Share Analysis

12.3. Market Size and Forecast

12.4. Market Size and Forecast, By Geography

12.4.1. North America

12.4.1.1. Market Share Analysis

12.4.1.2. Market Size and Forecast

12.4.1.3. By Product

12.4.1.4. By Technology

12.4.1.5. By Application

12.4.1.6. By Customer

12.4.1.7. United States

12.4.1.7.1. Market Share Analysis

12.4.1.7.2. Market Size and Forecast

12.4.1.7.3. By Product

12.4.1.7.4. By Technology

12.4.1.7.5. By Application

12.4.1.7.6. By Customer

12.4.1.7.7. Arizona (Scottsdale, Headquarters Cluster)

12.4.1.7.7.1. Market Share Analysis

12.4.1.7.7.2. Market Size and Forecast

12.4.1.7.7.3. By Product

12.4.1.7.7.4. By Technology

12.4.1.7.7.5. By Application

12.4.1.7.7.6. By Customer

12.4.1.7.8. California (San Francisco, San Diego, Biotech Clusters)

12.4.1.7.8.1. Market Share Analysis

12.4.1.7.8.2. Market Size and Forecast

12.4.1.7.8.3. By Product

12.4.1.7.8.4. By Technology

12.4.1.7.8.5. By Application

12.4.1.7.8.6. By Customer

12.4.1.7.9. Massachusetts (Boston/Cambridge, Clinical Trial Hubs)

12.4.1.7.9.1. Market Share Analysis

12.4.1.7.9.2. Market Size and Forecast

12.4.1.7.9.3. By Product

12.4.1.7.9.4. By Technology

12.4.1.7.9.5. By Application

12.4.1.7.9.6. By Customer

12.4.1.7.10. North Carolina (Research Triangle Park)

12.4.1.7.10.1. Market Share Analysis

12.4.1.7.10.2. Market Size and Forecast

12.4.1.7.10.3. By Product

12.4.1.7.10.4. By Technology

12.4.1.7.10.5. By Application

12.4.1.7.10.6. By Customer

12.4.2. Europe

12.4.2.1. Market Share Analysis

12.4.2.2. Market Size and Forecast

12.4.2.3. By Product

12.4.2.4. By Technology

12.4.2.5. By Application

12.4.2.6. By Customer

12.4.2.7. United Kingdom

12.4.2.7.1. Market Share Analysis

12.4.2.7.2. Market Size and Forecast

12.4.2.7.3. By Product

12.4.2.7.4. By Technology

12.4.2.7.5. By Application

12.4.2.7.6. By Customer

12.4.2.8. Germany

12.4.2.8.1. Market Share Analysis

12.4.2.8.2. Market Size and Forecast

12.4.2.8.3. By Product

12.4.2.8.4. By Technology

12.4.2.8.5. By Application

12.4.2.8.6. By Customer

12.4.2.9. France

12.4.2.9.1. Market Share Analysis

12.4.2.9.2. Market Size and Forecast

12.4.2.9.3. By Product

12.4.2.9.4. By Technology

12.4.2.9.5. By Application

12.4.2.9.6. By Customer

12.4.2.10. Switzerland

12.4.2.10.1. Market Share Analysis

12.4.2.10.2. Market Size and Forecast

12.4.2.10.3. By Product

12.4.2.10.4. By Technology

12.4.2.10.5. By Application

12.4.2.10.6. By Customer

12.4.2.11. Netherlands

12.4.2.11.1. Market Share Analysis

12.4.2.11.2. Market Size and Forecast

12.4.2.11.3. By Product

12.4.2.11.4. By Technology

12.4.2.11.5. By Application

12.4.2.11.6. By Customer

12.4.3. Asia-Pacific

12.4.3.1. Market Share Analysis

12.4.3.2. Market Size and Forecast

12.4.3.3. By Product

12.4.3.4. By Technology

12.4.3.5. By Application

12.4.3.6. By Customer

12.4.3.7. Japan

12.4.3.7.1. Market Share Analysis

12.4.3.7.2. Market Size and Forecast

12.4.3.7.3. By Product

12.4.3.7.4. By Technology

12.4.3.7.5. By Application

12.4.3.7.6. By Customer

12.4.3.8. China

12.4.3.8.1. Market Share Analysis

12.4.3.8.2. Market Size and Forecast

12.4.3.8.3. By Product

12.4.3.8.4. By Technology

12.4.3.8.5. By Application

12.4.3.8.6. By Customer

12.4.3.9. South Korea

12.4.3.9.1. Market Share Analysis

12.4.3.9.2. Market Size and Forecast

12.4.3.9.3. By Product

12.4.3.9.4. By Technology

12.4.3.9.5. By Application

12.4.3.9.6. By Customer

12.4.3.10. Australia

12.4.3.10.1. Market Share Analysis

12.4.3.10.2. Market Size and Forecast

12.4.3.10.3. By Product

12.4.3.10.4. By Technology

12.4.3.10.5. By Application

12.4.3.10.6. By Customer

12.4.3.11. India

12.4.3.11.1. Market Share Analysis

12.4.3.11.2. Market Size and Forecast

12.4.3.11.3. By Product

12.4.3.11.4. By Technology

12.4.3.11.5. By Application

12.4.3.11.6. By Customer

13. Competition Analysis

13.1. Market Positioning Overview

13.1.1. Label

13.1.2. Items

13.2. Competitive Benchmarking Metrics

13.2.1. Label

13.2.2. Items

13.3. Strategic Moves

13.3.1. Label

13.3.2. Items

13.4. Competitive Mapping & Gaps

13.4.1. Label

13.4.2. Items

14. Company Profiles

14.1. Imaging Endpoints

14.1.1. Overview

14.1.2. Footprint

14.1.3. Portfolio

14.1.4. Customers

14.1.5. Go-to-Market (GTM)

14.1.6. Certifications

14.1.7. Partnerships

14.1.8. Innovation

14.1.9. Developments

14.1.10. SWOT

14.2. ICON plc

14.2.1. Overview

14.2.2. Footprint

14.2.3. Portfolio

14.2.4. Customers

14.2.5. Go-to-Market (GTM)

14.2.6. Certifications

14.2.7. Partnerships

14.2.8. Innovation

14.2.9. Developments

14.2.10. SWOT

14.3. Parexel

14.3.1. Overview

14.3.2. Footprint

14.3.3. Portfolio

14.3.4. Customers

14.3.5. Go-to-Market (GTM)

14.3.6. Certifications

14.3.7. Partnerships

14.3.8. Innovation

14.3.9. Developments

14.3.10. SWOT

14.4. IQVIA

14.4.1. Overview

14.4.2. Footprint

14.4.3. Portfolio

14.4.4. Customers

14.4.5. Go-to-Market (GTM)

14.4.6. Certifications

14.4.7. Partnerships

14.4.8. Innovation

14.4.9. Developments

14.4.10. SWOT

14.5. Medpace

14.5.1. Overview

14.5.2. Footprint

14.5.3. Portfolio

14.5.4. Customers

14.5.5. Go-to-Market (GTM)

14.5.6. Certifications

14.5.7. Partnerships

14.5.8. Innovation

14.5.9. Developments

14.5.10. SWOT

14.6. BioClinica

14.6.1. Overview

14.6.2. Footprint

14.6.3. Portfolio

14.6.4. Customers

14.6.5. Go-to-Market (GTM)

14.6.6. Certifications

14.6.7. Partnerships

14.6.8. Innovation

14.6.9. Developments

14.6.10. SWOT

14.7. Arterys

14.7.1. Overview

14.7.2. Footprint

14.7.3. Portfolio

14.7.4. Customers

14.7.5. Go-to-Market (GTM)

14.7.6. Certifications

14.7.7. Partnerships

14.7.8. Innovation

14.7.9. Developments

14.7.10. SWOT

14.8. Lunit

14.8.1. Overview

14.8.2. Footprint

14.8.3. Portfolio

14.8.4. Customers

14.8.5. Go-to-Market (GTM)

14.8.6. Certifications

14.8.7. Partnerships

14.8.8. Innovation

14.8.9. Developments

14.8.10. SWOT

14.9. Aidoc

14.9.1. Overview

14.9.2. Footprint

14.9.3. Portfolio

14.9.4. Customers

14.9.5. Go-to-Market (GTM)

14.9.6. Certifications

14.9.7. Partnerships

14.9.8. Innovation

14.9.9. Developments

14.9.10. SWOT

14.10. Tempus

14.10.1. Overview

14.10.2. Footprint

14.10.3. Portfolio

14.10.4. Customers

14.10.5. Go-to-Market (GTM)

14.10.6. Certifications

14.10.7. Partnerships

14.10.8. Innovation

14.10.9. Developments

14.10.10. SWOT

14.11. Flywheel

14.11.1. Overview

14.11.2. Footprint

14.11.3. Portfolio

14.11.4. Customers

14.11.5. Go-to-Market (GTM)

14.11.6. Certifications

14.11.7. Partnerships

14.11.8. Innovation

14.11.9. Developments

14.11.10. SWOT

14.12. Qure.ai

14.12.1. Overview

14.12.2. Footprint

14.12.3. Portfolio

14.12.4. Customers

14.12.5. Go-to-Market (GTM)

14.12.6. Certifications

14.12.7. Partnerships

14.12.8. Innovation

14.12.9. Developments

14.12.10. SWOT

14.13. Subtle Medical

14.13.1. Overview

14.13.2. Footprint

14.13.3. Portfolio

14.13.4. Customers

14.13.5. Go-to-Market (GTM)

14.13.6. Certifications

14.13.7. Partnerships

14.13.8. Innovation

14.13.9. Developments

14.13.10. SWOT

Frequently Asked Questions

The market is estimated at approximately USD 950 Million in 2025 and is projected to reach approximately USD 2.05 Billion by 2030, expanding at a compound annual growth rate of roughly 16.6 percent.

The use of medical imaging, combined with AI-based analysis and radiomics, to generate and validate endpoints in oncology clinical trials. This report describes the category strictly as a market segment.

Growth in oncology drug development pipelines is the leading driver, sustaining demand for imaging biomarker quantification and trial endpoint validation.

North America accounts for the largest regional concentration, reflecting concentrated biotech and clinical trial hub activity across the United States.

Core lab imaging services account for the largest imaging service type category by revenue, and are generally specified across the widest range of trial phases and oncology indications.

AI-based tumor segmentation and volumetrics forms the fastest-growing AI/radiomics capability layer, reflecting rising demand for automated, quantitative tumor assessment.

Dependence on pharma and biotech clinical trial budgets outside any provider's control, long procurement cycles typically running 3 to 9 months, and regulatory delays, data variability and AI explainability concerns all bear directly on adoption pace.

Underpenetration in APAC oncology trials and a gap in integrated imaging and multi-omics analytics represent the widest remaining commercial gaps identified in this report's competitive mapping.

Inquire Before Buying Request Free Sample Ask For Discount

Clinical trial imaging separated from the broader diagnostic imaging and general CRO market

Clinical trial imaging and AI/radiomics services for oncology are frequently reported inside the much larger diagnostic imaging equipment or general clinical CRO markets, which span activity not comparable with the activity described here. This estimate covers clinical trial imaging and AI/radiomics analytics for oncology only. The snapshot table states that boundary so the figure is not mistaken for anything larger.

Derivation from active oncology trial population

Applying observed imaging service adoption rates per trial phase and oncology indication, weighted by imaging service type and business model, to the estimated population of qualifying oncology trials across the regions this report covers produces an annual range of approximately USD 930 to 970 million for clinical trial imaging service delivery itself.

AI-enabled and traditional imaging categories weighted separately

AI-enabled imaging and radiomics analytics carry a materially higher value per unit than traditional core lab imaging alone, and weighting the service mix by observed category share rather than by trial volume alone produces a total range of approximately USD 940 to 960 million, and USD 950 million was adopted near the midpoint.

Forecast basis and its principal sensitivity

The forecast to 2030 assumes global oncology drug development investment continues broadly on recent trends. Oncology R&D funding trajectory is the material sensitivity, since clinical trial imaging demand tracks this activity more closely than any single technology-level trend.

Frequently Asked Questions

The market is estimated at approximately USD 950 Million in 2025 and is projected to reach approximately USD 2.05 Billion by 2030, expanding at a compound annual growth rate of roughly 16.6 percent.

The use of medical imaging, combined with AI-based analysis and radiomics, to generate and validate endpoints in oncology clinical trials. This report describes the category strictly as a market segment.

Growth in oncology drug development pipelines is the leading driver, sustaining demand for imaging biomarker quantification and trial endpoint validation.

North America accounts for the largest regional concentration, reflecting concentrated biotech and clinical trial hub activity across the United States.

Core lab imaging services account for the largest imaging service type category by revenue, and are generally specified across the widest range of trial phases and oncology indications.

AI-based tumor segmentation and volumetrics forms the fastest-growing AI/radiomics capability layer, reflecting rising demand for automated, quantitative tumor assessment.

Dependence on pharma and biotech clinical trial budgets outside any provider's control, long procurement cycles typically running 3 to 9 months, and regulatory delays, data variability and AI explainability concerns all bear directly on adoption pace.

Underpenetration in APAC oncology trials and a gap in integrated imaging and multi-omics analytics represent the widest remaining commercial gaps identified in this report's competitive mapping.

Inquire Before Buying Request Free Sample Ask For Discount